Other · developed by Zenas BioPharma, LLC
ZB001 is an investigational agent given as intravenous injections at 3 mg/kg and 10 mg/kg dose cohorts. It is studied in thyroid eye disease, also known as Graves ophthalmopathy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05776121 | Phase 1 | Thyroid Eye Disease | Completed | ZBIO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Thyroid Eye Disease
Updated Nov 1, 2026. Something wrong or missing? Report it on the ZBIO page.
See ZBIO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ZBIO catalysts and pipeline →